FOR IMMEDIATE RELEASE
GLOBAL CANCER TECHNOLOGY RECEIVES U.S. PATENT FOR GCT-007, A NOVEL CANCER THERAPY TARGETING PI3K-DRIVEN CANCERS
Patent strengthens intellectual property portfolio and supports development of GCT-007 for aggressive and treatment-resistant cancers.
SAN DIEGO, Calif. – May 26, 2026 – Global Cancer Technology (GCT), a preclinical-stage biopharmaceutical company developing cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,637,450. The patent, titled “Tri-Substituted Aryl and Heteroaryl Derivatives as Modulators of PI3-Kinase and Autophagy Pathways,” protects the composition and use of GCT’s lead therapeutic candidate, GCT-007.
Patent Strengthens Development of GCT-007
The patent protects GCT-007, GCT’s next-generation phosphoinositide 3-kinase (PI3K) inhibitor. In addition, it expands the company’s intellectual property portfolio and supports future clinical development efforts.
GCT designed GCT-007 to target cancers driven by abnormal PI3K signaling. The company plans to advance the program toward a Phase I clinical trial.
Why the PI3K Pathway Matters
The PI3K pathway plays an important role in many cancers. Researchers have linked it to tumor growth, disease progression, recurrence, and resistance to treatment. Consequently, scientists continue to explore therapies that target this pathway.
GCT is developing GCT-007 for several aggressive cancers, including glioblastoma, drug-resistant breast cancer, and thyroid cancer. These diseases often have limited treatment options and significant unmet medical needs.
Milestone Reflects Innovative Science
“This patent issuance marks an important milestone for Global Cancer Technology and validates the novel chemistry behind GCT-007,” said Karen Newell Rogers, Ph.D., Chief Scientific Officer of Global Cancer Technology. “Furthermore, securing these patent claims highlights both the innovative design of this molecule and its potential to address cancers driven by PI3K dysregulation.”
Building Long-Term Value
John Clark, Founder and Chief Executive Officer of Global Cancer Technology, said the patent represents an important step in building long-term value around the company’s therapeutic platform.
“Strong intellectual property protection is essential for developing innovative medicines,” Clark said. “This patent strengthens our ability to advance GCT-007 through clinical development. In addition, our collaboration with researchers at The University of Texas MD Anderson Cancer Center and our preparations for a Phase I clinical trial position Global Cancer Technology for meaningful progress in the years ahead.”
The patent originated from U.S. Application No. 18/741,572, which the company filed on June 12, 2024.
About Global Cancer Technology
Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on developing therapies for aggressive and treatment-resistant cancers. Its lead therapeutic candidate, GCT-007, is a next-generation PI3K inhibitor with potential applications across several cancers linked to PI3K pathway dysregulation. The company is preparing for a Phase I clinical trial while pursuing strategic collaborations to accelerate development.
For more information, visit www.globalcancertechnology.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include the potential therapeutic benefits of GCT-007, future clinical development activities, fundraising initiatives, and the expected impact of the company’s intellectual property portfolio. However, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Accordingly, there can be no assurance that GCT-007 will successfully complete development, receive regulatory approval, or achieve commercial success.
